nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—ABCB1—Mitomycin—urinary bladder cancer	0.182	0.338	CbGbCtD
Rivaroxaban—CYP3A4—Thiotepa—urinary bladder cancer	0.0826	0.154	CbGbCtD
Rivaroxaban—CYP3A5—Etoposide—urinary bladder cancer	0.0574	0.107	CbGbCtD
Rivaroxaban—ABCB1—Gemcitabine—urinary bladder cancer	0.0524	0.0974	CbGbCtD
Rivaroxaban—ABCB1—Cisplatin—urinary bladder cancer	0.0381	0.0708	CbGbCtD
Rivaroxaban—ABCB1—Etoposide—urinary bladder cancer	0.0374	0.0695	CbGbCtD
Rivaroxaban—ABCB1—Doxorubicin—urinary bladder cancer	0.0255	0.0474	CbGbCtD
Rivaroxaban—ABCB1—Methotrexate—urinary bladder cancer	0.0247	0.0459	CbGbCtD
Rivaroxaban—CYP3A4—Etoposide—urinary bladder cancer	0.0224	0.0417	CbGbCtD
Rivaroxaban—CYP3A4—Doxorubicin—urinary bladder cancer	0.0153	0.0284	CbGbCtD
Rivaroxaban—F10—prostate gland—urinary bladder cancer	0.00805	0.143	CbGeAlD
Rivaroxaban—CYP2J2—prostate gland—urinary bladder cancer	0.0066	0.117	CbGeAlD
Rivaroxaban—F10—urethra—urinary bladder cancer	0.00539	0.0955	CbGeAlD
Rivaroxaban—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00515	0.0361	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00492	0.0345	CbGpPWpGaD
Rivaroxaban—CYP3A4—urine—urinary bladder cancer	0.00485	0.0861	CbGeAlD
Rivaroxaban—F10—female reproductive system—urinary bladder cancer	0.00439	0.0779	CbGeAlD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00426	0.0298	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.0042	0.0294	CbGpPWpGaD
Rivaroxaban—F10—vagina—urinary bladder cancer	0.00397	0.0704	CbGeAlD
Rivaroxaban—CYP2J2—female reproductive system—urinary bladder cancer	0.0036	0.0638	CbGeAlD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00345	0.0242	CbGpPWpGaD
Rivaroxaban—CYP2J2—vagina—urinary bladder cancer	0.00326	0.0577	CbGeAlD
Rivaroxaban—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00317	0.0223	CbGpPWpGaD
Rivaroxaban—CYP3A5—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00316	0.0221	CbGpPWpGaD
Rivaroxaban—F10—Blood Clotting Cascade—PLAU—urinary bladder cancer	0.00265	0.0185	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00262	0.0184	CbGpPWpGaD
Rivaroxaban—F10—lymph node—urinary bladder cancer	0.00257	0.0456	CbGeAlD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00256	0.0179	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GSTZ1—urinary bladder cancer	0.00235	0.0165	CbGpPWpGaD
Rivaroxaban—CYP3A5—prostate gland—urinary bladder cancer	0.00232	0.0412	CbGeAlD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00232	0.0162	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GSTO2—urinary bladder cancer	0.00223	0.0156	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—NAT1—urinary bladder cancer	0.00223	0.0156	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00219	0.0154	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—PLAU—urinary bladder cancer	0.00212	0.0149	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—UGT2B7—urinary bladder cancer	0.00204	0.0143	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00201	0.0141	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP4B1—urinary bladder cancer	0.00183	0.0128	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00181	0.0127	CbGpPWpGaD
Rivaroxaban—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00166	0.0116	CbGpPWpGaD
Rivaroxaban—CYP3A5—renal system—urinary bladder cancer	0.00158	0.0281	CbGeAlD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00155	0.0109	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00147	0.0103	CbGpPWpGaD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00146	0.0102	CbGpPWpGaD
Rivaroxaban—ABCB1—prostate gland—urinary bladder cancer	0.00123	0.0219	CbGeAlD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00123	0.0086	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—NAT2—urinary bladder cancer	0.00122	0.00855	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00121	0.00848	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.0012	0.00843	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—PLAU—urinary bladder cancer	0.0012	0.00842	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00119	0.00834	CbGpPWpGaD
Rivaroxaban—CYP3A4—renal system—urinary bladder cancer	0.00119	0.0211	CbGeAlD
Rivaroxaban—CYP3A5—vagina—urinary bladder cancer	0.00115	0.0203	CbGeAlD
Rivaroxaban—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00105	0.00733	CbGpPWpGaD
Rivaroxaban—ABCB1—seminal vesicle—urinary bladder cancer	0.00104	0.0185	CbGeAlD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000994	0.00697	CbGpPWpGaD
Rivaroxaban—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00099	0.00694	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—HPGDS—urinary bladder cancer	0.000975	0.00683	CbGpPWpGaD
Rivaroxaban—CYP3A4—female reproductive system—urinary bladder cancer	0.000951	0.0169	CbGeAlD
Rivaroxaban—CYP2J2—Biological oxidations—GSTT1—urinary bladder cancer	0.000945	0.00663	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000912	0.00639	CbGpPWpGaD
Rivaroxaban—ABCB1—epithelium—urinary bladder cancer	0.000907	0.0161	CbGeAlD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000898	0.0063	CbGpPWpGaD
Rivaroxaban—ABCB1—renal system—urinary bladder cancer	0.000841	0.0149	CbGeAlD
Rivaroxaban—ABCB1—urethra—urinary bladder cancer	0.000826	0.0146	CbGeAlD
Rivaroxaban—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000747	0.00524	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000704	0.00493	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.000677	0.00474	CbGpPWpGaD
Rivaroxaban—ABCB1—female reproductive system—urinary bladder cancer	0.000673	0.0119	CbGeAlD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000667	0.00468	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GSTP1—urinary bladder cancer	0.000655	0.00459	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000646	0.00453	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.000641	0.0045	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.000641	0.0045	CbGpPWpGaD
Rivaroxaban—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000641	0.00449	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000633	0.00443	CbGpPWpGaD
Rivaroxaban—ABCB1—vagina—urinary bladder cancer	0.000609	0.0108	CbGeAlD
Rivaroxaban—CYP2J2—Biological oxidations—GSTM1—urinary bladder cancer	0.000602	0.00422	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000594	0.00416	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.000587	0.00411	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000579	0.00406	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00057	0.004	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000563	0.00394	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.000528	0.0037	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000521	0.00365	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CDX2—urinary bladder cancer	0.00052	0.00364	CbGpPWpGaD
Rivaroxaban—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000491	0.00344	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000462	0.00324	CbGpPWpGaD
Rivaroxaban—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00046	0.00323	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000415	0.00291	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTZ1—urinary bladder cancer	0.000401	0.00281	CbGpPWpGaD
Rivaroxaban—Hypotension—Cisplatin—urinary bladder cancer	0.000399	0.00152	CcSEcCtD
Rivaroxaban—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000397	0.00151	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000396	0.0015	CcSEcCtD
Rivaroxaban—Fatigue—Gemcitabine—urinary bladder cancer	0.000395	0.0015	CcSEcCtD
Rivaroxaban—ABCB1—lymph node—urinary bladder cancer	0.000394	0.00698	CbGeAlD
Rivaroxaban—Pain—Gemcitabine—urinary bladder cancer	0.000392	0.00149	CcSEcCtD
Rivaroxaban—Constipation—Gemcitabine—urinary bladder cancer	0.000392	0.00149	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000391	0.00149	CcSEcCtD
Rivaroxaban—Asthenia—Thiotepa—urinary bladder cancer	0.000391	0.00149	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000389	0.00148	CcSEcCtD
Rivaroxaban—Infection—Etoposide—urinary bladder cancer	0.000389	0.00148	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000387	0.00147	CcSEcCtD
Rivaroxaban—Pruritus—Thiotepa—urinary bladder cancer	0.000386	0.00146	CcSEcCtD
Rivaroxaban—Pain—Fluorouracil—urinary bladder cancer	0.000385	0.00146	CcSEcCtD
Rivaroxaban—Tachycardia—Etoposide—urinary bladder cancer	0.000382	0.00145	CcSEcCtD
Rivaroxaban—Dyspnoea—Cisplatin—urinary bladder cancer	0.000381	0.00145	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—GSTO2—urinary bladder cancer	0.000381	0.00267	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NAT1—urinary bladder cancer	0.000381	0.00267	CbGpPWpGaD
Rivaroxaban—Skin disorder—Etoposide—urinary bladder cancer	0.00038	0.00144	CcSEcCtD
Rivaroxaban—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000378	0.00143	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000377	0.00143	CcSEcCtD
Rivaroxaban—Angina pectoris—Epirubicin—urinary bladder cancer	0.000376	0.00143	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000374	0.00262	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Thiotepa—urinary bladder cancer	0.000373	0.00142	CcSEcCtD
Rivaroxaban—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000371	0.00141	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000369	0.0014	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—urinary bladder cancer	0.000368	0.0014	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—urinary bladder cancer	0.000368	0.0014	CcSEcCtD
Rivaroxaban—Hypotension—Etoposide—urinary bladder cancer	0.000366	0.00139	CcSEcCtD
Rivaroxaban—Pain—Cisplatin—urinary bladder cancer	0.000365	0.00139	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000364	0.00138	CcSEcCtD
Rivaroxaban—Renal failure—Methotrexate—urinary bladder cancer	0.000361	0.00137	CcSEcCtD
Rivaroxaban—Dizziness—Thiotepa—urinary bladder cancer	0.00036	0.00137	CcSEcCtD
Rivaroxaban—Urticaria—Fluorouracil—urinary bladder cancer	0.000358	0.00136	CcSEcCtD
Rivaroxaban—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000352	0.00134	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000351	0.00246	CbGpPWpGaD
Rivaroxaban—Haematuria—Methotrexate—urinary bladder cancer	0.000351	0.00133	CcSEcCtD
Rivaroxaban—Dyspnoea—Etoposide—urinary bladder cancer	0.000349	0.00133	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—UGT2B7—urinary bladder cancer	0.000348	0.00244	CbGpPWpGaD
Rivaroxaban—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000348	0.00132	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000348	0.00132	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—urinary bladder cancer	0.000347	0.00132	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000347	0.00243	CbGpPWpGaD
Rivaroxaban—Vomiting—Thiotepa—urinary bladder cancer	0.000346	0.00132	CcSEcCtD
Rivaroxaban—Infestation NOS—Epirubicin—urinary bladder cancer	0.000344	0.00131	CcSEcCtD
Rivaroxaban—Infestation—Epirubicin—urinary bladder cancer	0.000344	0.00131	CcSEcCtD
Rivaroxaban—Rash—Thiotepa—urinary bladder cancer	0.000344	0.00131	CcSEcCtD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000343	0.00241	CbGpPWpGaD
Rivaroxaban—Dermatitis—Thiotepa—urinary bladder cancer	0.000343	0.0013	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000343	0.0013	CcSEcCtD
Rivaroxaban—Headache—Thiotepa—urinary bladder cancer	0.000341	0.0013	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000341	0.0013	CcSEcCtD
Rivaroxaban—Renal failure—Epirubicin—urinary bladder cancer	0.000338	0.00128	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000338	0.00128	CcSEcCtD
Rivaroxaban—Fatigue—Etoposide—urinary bladder cancer	0.000337	0.00128	CcSEcCtD
Rivaroxaban—Jaundice—Epirubicin—urinary bladder cancer	0.000335	0.00127	CcSEcCtD
Rivaroxaban—Pain—Etoposide—urinary bladder cancer	0.000335	0.00127	CcSEcCtD
Rivaroxaban—Constipation—Etoposide—urinary bladder cancer	0.000335	0.00127	CcSEcCtD
Rivaroxaban—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000334	0.00127	CcSEcCtD
Rivaroxaban—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000332	0.00126	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—urinary bladder cancer	0.000332	0.00126	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—urinary bladder cancer	0.00033	0.00125	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—urinary bladder cancer	0.00033	0.00125	CcSEcCtD
Rivaroxaban—Asthenia—Gemcitabine—urinary bladder cancer	0.000329	0.00125	CcSEcCtD
Rivaroxaban—Haematuria—Epirubicin—urinary bladder cancer	0.000328	0.00125	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000326	0.00229	CbGpPWpGaD
Rivaroxaban—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000326	0.00124	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000325	0.00124	CcSEcCtD
Rivaroxaban—Epistaxis—Epirubicin—urinary bladder cancer	0.000324	0.00123	CcSEcCtD
Rivaroxaban—Pruritus—Gemcitabine—urinary bladder cancer	0.000324	0.00123	CcSEcCtD
Rivaroxaban—Nausea—Thiotepa—urinary bladder cancer	0.000324	0.00123	CcSEcCtD
Rivaroxaban—Urethral disorder—Methotrexate—urinary bladder cancer	0.000323	0.00123	CcSEcCtD
Rivaroxaban—Sinusitis—Epirubicin—urinary bladder cancer	0.000323	0.00123	CcSEcCtD
Rivaroxaban—Feeling abnormal—Etoposide—urinary bladder cancer	0.000323	0.00123	CcSEcCtD
Rivaroxaban—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000321	0.00122	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00032	0.00122	CcSEcCtD
Rivaroxaban—Pruritus—Fluorouracil—urinary bladder cancer	0.000319	0.00121	CcSEcCtD
Rivaroxaban—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000318	0.00121	CcSEcCtD
Rivaroxaban—Infestation—Doxorubicin—urinary bladder cancer	0.000318	0.00121	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000316	0.0012	CcSEcCtD
Rivaroxaban—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000315	0.0012	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000315	0.0022	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000314	0.00119	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CYP4B1—urinary bladder cancer	0.000313	0.0022	CbGpPWpGaD
Rivaroxaban—Renal failure—Doxorubicin—urinary bladder cancer	0.000313	0.00119	CcSEcCtD
Rivaroxaban—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000312	0.00119	CcSEcCtD
Rivaroxaban—Urticaria—Etoposide—urinary bladder cancer	0.000311	0.00118	CcSEcCtD
Rivaroxaban—Haemoglobin—Epirubicin—urinary bladder cancer	0.00031	0.00118	CcSEcCtD
Rivaroxaban—Jaundice—Doxorubicin—urinary bladder cancer	0.00031	0.00118	CcSEcCtD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00031	0.00217	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Etoposide—urinary bladder cancer	0.000309	0.00118	CcSEcCtD
Rivaroxaban—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000309	0.00118	CcSEcCtD
Rivaroxaban—Haemorrhage—Epirubicin—urinary bladder cancer	0.000309	0.00117	CcSEcCtD
Rivaroxaban—Hepatitis—Epirubicin—urinary bladder cancer	0.000309	0.00117	CcSEcCtD
Rivaroxaban—Eye disorder—Methotrexate—urinary bladder cancer	0.000308	0.00117	CcSEcCtD
Rivaroxaban—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000308	0.00117	CcSEcCtD
Rivaroxaban—Asthenia—Cisplatin—urinary bladder cancer	0.000307	0.00116	CcSEcCtD
Rivaroxaban—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000306	0.00116	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000305	0.00116	CcSEcCtD
Rivaroxaban—Haematuria—Doxorubicin—urinary bladder cancer	0.000304	0.00115	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000303	0.00115	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IFNA2—urinary bladder cancer	0.000303	0.00213	CbGpPWpGaD
Rivaroxaban—Urethral disorder—Epirubicin—urinary bladder cancer	0.000303	0.00115	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000301	0.00114	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—urinary bladder cancer	0.0003	0.00114	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—urinary bladder cancer	0.000299	0.00114	CcSEcCtD
Rivaroxaban—Sinusitis—Doxorubicin—urinary bladder cancer	0.000299	0.00113	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000298	0.00209	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000298	0.00209	CbGpPWpGaD
Rivaroxaban—Immune system disorder—Methotrexate—urinary bladder cancer	0.000298	0.00113	CcSEcCtD
Rivaroxaban—Dizziness—Fluorouracil—urinary bladder cancer	0.000298	0.00113	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000297	0.00113	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000297	0.00113	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—SLC19A1—urinary bladder cancer	0.000296	0.00207	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000294	0.00206	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Cisplatin—urinary bladder cancer	0.000292	0.00111	CcSEcCtD
Rivaroxaban—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000292	0.00111	CcSEcCtD
Rivaroxaban—Vomiting—Gemcitabine—urinary bladder cancer	0.000291	0.00111	CcSEcCtD
Rivaroxaban—Rash—Gemcitabine—urinary bladder cancer	0.000289	0.0011	CcSEcCtD
Rivaroxaban—Dermatitis—Gemcitabine—urinary bladder cancer	0.000289	0.0011	CcSEcCtD
Rivaroxaban—Eye disorder—Epirubicin—urinary bladder cancer	0.000289	0.0011	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—PRSS3—urinary bladder cancer	0.000288	0.00202	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Etoposide—urinary bladder cancer	0.000288	0.0011	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000287	0.00109	CcSEcCtD
Rivaroxaban—Headache—Gemcitabine—urinary bladder cancer	0.000287	0.00109	CcSEcCtD
Rivaroxaban—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000287	0.00109	CcSEcCtD
Rivaroxaban—Vomiting—Fluorouracil—urinary bladder cancer	0.000287	0.00109	CcSEcCtD
Rivaroxaban—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000286	0.00109	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—urinary bladder cancer	0.000286	0.00109	CcSEcCtD
Rivaroxaban—Rash—Fluorouracil—urinary bladder cancer	0.000284	0.00108	CcSEcCtD
Rivaroxaban—Dermatitis—Fluorouracil—urinary bladder cancer	0.000284	0.00108	CcSEcCtD
Rivaroxaban—Headache—Fluorouracil—urinary bladder cancer	0.000282	0.00107	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000282	0.00107	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000281	0.00197	CbGpPWpGaD
Rivaroxaban—Asthenia—Etoposide—urinary bladder cancer	0.000281	0.00107	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000281	0.00107	CcSEcCtD
Rivaroxaban—Angiopathy—Epirubicin—urinary bladder cancer	0.00028	0.00106	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00028	0.00106	CcSEcCtD
Rivaroxaban—Immune system disorder—Epirubicin—urinary bladder cancer	0.000279	0.00106	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000278	0.00106	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—urinary bladder cancer	0.000278	0.00106	CcSEcCtD
Rivaroxaban—Pruritus—Etoposide—urinary bladder cancer	0.000277	0.00105	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000273	0.00191	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.000273	0.00191	CbGpPWpGaD
Rivaroxaban—Nausea—Gemcitabine—urinary bladder cancer	0.000272	0.00103	CcSEcCtD
Rivaroxaban—Vomiting—Cisplatin—urinary bladder cancer	0.000272	0.00103	CcSEcCtD
Rivaroxaban—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00027	0.00103	CcSEcCtD
Rivaroxaban—Rash—Cisplatin—urinary bladder cancer	0.000269	0.00102	CcSEcCtD
Rivaroxaban—Dermatitis—Cisplatin—urinary bladder cancer	0.000269	0.00102	CcSEcCtD
Rivaroxaban—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000269	0.00189	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Etoposide—urinary bladder cancer	0.000268	0.00102	CcSEcCtD
Rivaroxaban—Nausea—Fluorouracil—urinary bladder cancer	0.000268	0.00102	CcSEcCtD
Rivaroxaban—Eye disorder—Doxorubicin—urinary bladder cancer	0.000267	0.00101	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000267	0.00101	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—urinary bladder cancer	0.000266	0.00101	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000265	0.00101	CcSEcCtD
Rivaroxaban—Back pain—Epirubicin—urinary bladder cancer	0.00026	0.000988	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—urinary bladder cancer	0.000259	0.000985	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—urinary bladder cancer	0.000259	0.000984	CcSEcCtD
Rivaroxaban—Dizziness—Etoposide—urinary bladder cancer	0.000259	0.000983	CcSEcCtD
Rivaroxaban—Muscle spasms—Epirubicin—urinary bladder cancer	0.000258	0.000982	CcSEcCtD
Rivaroxaban—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000258	0.00098	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000258	0.000978	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000256	0.00179	CbGpPWpGaD
Rivaroxaban—Nausea—Cisplatin—urinary bladder cancer	0.000254	0.000964	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000249	0.000947	CcSEcCtD
Rivaroxaban—Vomiting—Etoposide—urinary bladder cancer	0.000249	0.000945	CcSEcCtD
Rivaroxaban—Anaemia—Epirubicin—urinary bladder cancer	0.000248	0.000944	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000248	0.00174	CbGpPWpGaD
Rivaroxaban—Rash—Etoposide—urinary bladder cancer	0.000247	0.000937	CcSEcCtD
Rivaroxaban—Dermatitis—Etoposide—urinary bladder cancer	0.000247	0.000937	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000246	0.00172	CbGpPWpGaD
Rivaroxaban—Headache—Etoposide—urinary bladder cancer	0.000245	0.000931	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—urinary bladder cancer	0.000245	0.000929	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000243	0.000923	CcSEcCtD
Rivaroxaban—Malaise—Epirubicin—urinary bladder cancer	0.000242	0.000921	CcSEcCtD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000242	0.0017	CbGpPWpGaD
Rivaroxaban—Discomfort—Methotrexate—urinary bladder cancer	0.000242	0.000918	CcSEcCtD
Rivaroxaban—Syncope—Epirubicin—urinary bladder cancer	0.000241	0.000916	CcSEcCtD
Rivaroxaban—Back pain—Doxorubicin—urinary bladder cancer	0.000241	0.000914	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000239	0.000908	CcSEcCtD
Rivaroxaban—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000236	0.000898	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000234	0.000891	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—urinary bladder cancer	0.000233	0.000885	CcSEcCtD
Rivaroxaban—Nausea—Etoposide—urinary bladder cancer	0.000233	0.000883	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000231	0.00162	CbGpPWpGaD
Rivaroxaban—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000231	0.000877	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—TYMP—urinary bladder cancer	0.000231	0.00162	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00023	0.000873	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—urinary bladder cancer	0.00023	0.000873	CcSEcCtD
Rivaroxaban—Chest pain—Epirubicin—urinary bladder cancer	0.000229	0.000869	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—urinary bladder cancer	0.000228	0.000865	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000227	0.000863	CcSEcCtD
Rivaroxaban—Discomfort—Epirubicin—urinary bladder cancer	0.000226	0.000859	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—urinary bladder cancer	0.000224	0.000852	CcSEcCtD
Rivaroxaban—Dry mouth—Epirubicin—urinary bladder cancer	0.000224	0.00085	CcSEcCtD
Rivaroxaban—Syncope—Doxorubicin—urinary bladder cancer	0.000223	0.000847	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000221	0.00155	CbGpPWpGaD
Rivaroxaban—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000219	0.000833	CcSEcCtD
Rivaroxaban—Oedema—Epirubicin—urinary bladder cancer	0.000219	0.000833	CcSEcCtD
Rivaroxaban—Hypotension—Methotrexate—urinary bladder cancer	0.000219	0.000832	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000219	0.00153	CbGpPWpGaD
Rivaroxaban—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000219	0.00083	CcSEcCtD
Rivaroxaban—Infection—Epirubicin—urinary bladder cancer	0.000218	0.000828	CcSEcCtD
Rivaroxaban—Shock—Epirubicin—urinary bladder cancer	0.000216	0.00082	CcSEcCtD
Rivaroxaban—F10—Hemostasis—PLAU—urinary bladder cancer	0.000215	0.00151	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000215	0.000817	CcSEcCtD
Rivaroxaban—Tachycardia—Epirubicin—urinary bladder cancer	0.000214	0.000813	CcSEcCtD
Rivaroxaban—Skin disorder—Epirubicin—urinary bladder cancer	0.000213	0.00081	CcSEcCtD
Rivaroxaban—Chest pain—Doxorubicin—urinary bladder cancer	0.000212	0.000804	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000212	0.00148	CbGpPWpGaD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00021	0.000799	CcSEcCtD
Rivaroxaban—Discomfort—Doxorubicin—urinary bladder cancer	0.000209	0.000795	CcSEcCtD
Rivaroxaban—Dyspnoea—Methotrexate—urinary bladder cancer	0.000209	0.000794	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—NAT2—urinary bladder cancer	0.000209	0.00146	CbGpPWpGaD
Rivaroxaban—Dry mouth—Doxorubicin—urinary bladder cancer	0.000207	0.000787	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—urinary bladder cancer	0.000206	0.000784	CcSEcCtD
Rivaroxaban—Hypotension—Epirubicin—urinary bladder cancer	0.000205	0.000779	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000203	0.000771	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—urinary bladder cancer	0.000203	0.000771	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000202	0.000769	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—urinary bladder cancer	0.000202	0.000768	CcSEcCtD
Rivaroxaban—Infection—Doxorubicin—urinary bladder cancer	0.000202	0.000766	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—urinary bladder cancer	0.0002	0.000762	CcSEcCtD
Rivaroxaban—Shock—Doxorubicin—urinary bladder cancer	0.0002	0.000759	CcSEcCtD
Rivaroxaban—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000199	0.000756	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—urinary bladder cancer	0.000198	0.000753	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—urinary bladder cancer	0.000197	0.000749	CcSEcCtD
Rivaroxaban—Dyspnoea—Epirubicin—urinary bladder cancer	0.000196	0.000743	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000195	0.00137	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000194	0.00136	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000194	0.00136	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000193	0.000734	CcSEcCtD
Rivaroxaban—Dyspepsia—Epirubicin—urinary bladder cancer	0.000193	0.000734	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000192	0.000728	CcSEcCtD
Rivaroxaban—Hypotension—Doxorubicin—urinary bladder cancer	0.00019	0.000721	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000189	0.00072	CcSEcCtD
Rivaroxaban—Fatigue—Epirubicin—urinary bladder cancer	0.000189	0.000719	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000189	0.00132	CbGpPWpGaD
Rivaroxaban—Pain—Epirubicin—urinary bladder cancer	0.000188	0.000713	CcSEcCtD
Rivaroxaban—Constipation—Epirubicin—urinary bladder cancer	0.000188	0.000713	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000186	0.00131	CbGpPWpGaD
Rivaroxaban—Urticaria—Methotrexate—urinary bladder cancer	0.000186	0.000707	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—urinary bladder cancer	0.000185	0.000704	CcSEcCtD
Rivaroxaban—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000181	0.000687	CcSEcCtD
Rivaroxaban—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000181	0.000687	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—RRM2—urinary bladder cancer	0.00018	0.00126	CbGpPWpGaD
Rivaroxaban—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000179	0.000681	CcSEcCtD
Rivaroxaban—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000179	0.000679	CcSEcCtD
Rivaroxaban—F10—Hemostasis—CREBBP—urinary bladder cancer	0.000178	0.00125	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000177	0.00124	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IGF1—urinary bladder cancer	0.000175	0.00123	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000175	0.000666	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—urinary bladder cancer	0.000175	0.000665	CcSEcCtD
Rivaroxaban—Urticaria—Epirubicin—urinary bladder cancer	0.000174	0.000662	CcSEcCtD
Rivaroxaban—Constipation—Doxorubicin—urinary bladder cancer	0.000174	0.000659	CcSEcCtD
Rivaroxaban—Pain—Doxorubicin—urinary bladder cancer	0.000174	0.000659	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000174	0.00122	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Epirubicin—urinary bladder cancer	0.000173	0.000659	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000173	0.000656	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000171	0.0012	CbGpPWpGaD
Rivaroxaban—Asthenia—Methotrexate—urinary bladder cancer	0.000168	0.000639	CcSEcCtD
Rivaroxaban—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000167	0.000635	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ENO2—urinary bladder cancer	0.000167	0.00117	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—HPGDS—urinary bladder cancer	0.000167	0.00117	CbGpPWpGaD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000166	0.000631	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—urinary bladder cancer	0.000166	0.00063	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000166	0.00116	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000163	0.00115	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTT1—urinary bladder cancer	0.000162	0.00113	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000162	0.000614	CcSEcCtD
Rivaroxaban—Urticaria—Doxorubicin—urinary bladder cancer	0.000161	0.000613	CcSEcCtD
Rivaroxaban—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000161	0.00113	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—RHOA—urinary bladder cancer	0.000161	0.00113	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00016	0.00061	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—urinary bladder cancer	0.00016	0.000609	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000159	0.00112	CbGpPWpGaD
Rivaroxaban—Asthenia—Epirubicin—urinary bladder cancer	0.000157	0.000598	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000156	0.00109	CbGpPWpGaD
Rivaroxaban—Pruritus—Epirubicin—urinary bladder cancer	0.000155	0.00059	CcSEcCtD
Rivaroxaban—Dizziness—Methotrexate—urinary bladder cancer	0.000155	0.000589	CcSEcCtD
Rivaroxaban—Diarrhoea—Epirubicin—urinary bladder cancer	0.00015	0.00057	CcSEcCtD
Rivaroxaban—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00015	0.000568	CcSEcCtD
Rivaroxaban—Vomiting—Methotrexate—urinary bladder cancer	0.000149	0.000566	CcSEcCtD
Rivaroxaban—Rash—Methotrexate—urinary bladder cancer	0.000148	0.000562	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—urinary bladder cancer	0.000148	0.000561	CcSEcCtD
Rivaroxaban—Headache—Methotrexate—urinary bladder cancer	0.000147	0.000558	CcSEcCtD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000146	0.00102	CbGpPWpGaD
Rivaroxaban—Asthenia—Doxorubicin—urinary bladder cancer	0.000146	0.000553	CcSEcCtD
Rivaroxaban—Dizziness—Epirubicin—urinary bladder cancer	0.000145	0.000551	CcSEcCtD
Rivaroxaban—Pruritus—Doxorubicin—urinary bladder cancer	0.000144	0.000546	CcSEcCtD
Rivaroxaban—Vomiting—Epirubicin—urinary bladder cancer	0.00014	0.00053	CcSEcCtD
Rivaroxaban—Nausea—Methotrexate—urinary bladder cancer	0.000139	0.000529	CcSEcCtD
Rivaroxaban—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000139	0.000528	CcSEcCtD
Rivaroxaban—Rash—Epirubicin—urinary bladder cancer	0.000138	0.000525	CcSEcCtD
Rivaroxaban—Dermatitis—Epirubicin—urinary bladder cancer	0.000138	0.000525	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—IGF1—urinary bladder cancer	0.000138	0.000967	CbGpPWpGaD
Rivaroxaban—Headache—Epirubicin—urinary bladder cancer	0.000137	0.000522	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IL2—urinary bladder cancer	0.000135	0.000945	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NQO1—urinary bladder cancer	0.000134	0.000942	CbGpPWpGaD
Rivaroxaban—Dizziness—Doxorubicin—urinary bladder cancer	0.000134	0.00051	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000133	0.000935	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000132	0.000926	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000131	0.000915	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.00013	0.000914	CbGpPWpGaD
Rivaroxaban—Nausea—Epirubicin—urinary bladder cancer	0.00013	0.000495	CcSEcCtD
Rivaroxaban—Vomiting—Doxorubicin—urinary bladder cancer	0.000129	0.00049	CcSEcCtD
Rivaroxaban—Rash—Doxorubicin—urinary bladder cancer	0.000128	0.000486	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—urinary bladder cancer	0.000128	0.000486	CcSEcCtD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000128	0.000895	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	0.000128	0.000894	CbGpPWpGaD
Rivaroxaban—Headache—Doxorubicin—urinary bladder cancer	0.000127	0.000483	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000127	0.000888	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000124	0.00087	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000122	0.000854	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—EP300—urinary bladder cancer	0.000121	0.000848	CbGpPWpGaD
Rivaroxaban—Nausea—Doxorubicin—urinary bladder cancer	0.000121	0.000458	CcSEcCtD
Rivaroxaban—F10—Hemostasis—SRC—urinary bladder cancer	0.000118	0.000825	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000116	0.000811	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000114	0.000797	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTP1—urinary bladder cancer	0.000112	0.000786	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000111	0.000778	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.00011	0.000769	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.00011	0.000769	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000108	0.00076	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000108	0.000757	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—TYMS—urinary bladder cancer	0.000104	0.00073	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000104	0.00073	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NCOR1—urinary bladder cancer	0.000103	0.000722	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTM1—urinary bladder cancer	0.000103	0.000722	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.0001	0.000703	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GPX1—urinary bladder cancer	9.86e-05	0.000691	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—KRAS—urinary bladder cancer	9.74e-05	0.000683	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ERCC2—urinary bladder cancer	9.68e-05	0.000679	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	9.54e-05	0.000669	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	9.5e-05	0.000666	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	9.46e-05	0.000663	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	9.29e-05	0.000651	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—MTHFR—urinary bladder cancer	9.1e-05	0.000638	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	9.03e-05	0.000633	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.78e-05	0.000615	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	8.73e-05	0.000612	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.66e-05	0.000607	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—urinary bladder cancer	8.66e-05	0.000607	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	8.53e-05	0.000598	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	8.31e-05	0.000583	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	8.29e-05	0.000581	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—HRAS—urinary bladder cancer	8.28e-05	0.00058	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTO2—urinary bladder cancer	8.28e-05	0.00058	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NAT1—urinary bladder cancer	8.28e-05	0.00058	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	8.19e-05	0.000574	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	8.07e-05	0.000566	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.96e-05	0.000558	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	7.57e-05	0.000531	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PPARG—urinary bladder cancer	7.38e-05	0.000517	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CREBBP—urinary bladder cancer	7.09e-05	0.000497	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.04e-05	0.000493	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.94e-05	0.000487	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	6.82e-05	0.000478	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.79e-05	0.000476	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TYMP—urinary bladder cancer	6.65e-05	0.000466	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	6.44e-05	0.000451	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PRSS3—urinary bladder cancer	6.27e-05	0.00044	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	6.14e-05	0.00043	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NAT2—urinary bladder cancer	6.01e-05	0.000421	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.94e-05	0.000416	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.92e-05	0.000415	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—urinary bladder cancer	5.81e-05	0.000407	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.65e-05	0.000396	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.49e-05	0.000385	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.38e-05	0.000377	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—RRM2—urinary bladder cancer	5.19e-05	0.000364	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.1e-05	0.000357	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.1e-05	0.000357	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—urinary bladder cancer	5.06e-05	0.000355	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TYMP—urinary bladder cancer	5.01e-05	0.000351	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.92e-05	0.000345	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—EP300—urinary bladder cancer	4.83e-05	0.000338	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.81e-05	0.000337	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.8e-05	0.000337	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.8e-05	0.000337	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.66e-05	0.000327	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.66e-05	0.000327	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.58e-05	0.000321	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.55e-05	0.000319	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NAT2—urinary bladder cancer	4.54e-05	0.000318	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.2e-05	0.000294	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.04e-05	0.000283	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.97e-05	0.000278	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.91e-05	0.000274	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.87e-05	0.000271	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.86e-05	0.000271	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.63e-05	0.000254	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.63e-05	0.000254	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.52e-05	0.000246	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.29e-05	0.000231	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	3.23e-05	0.000226	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.09e-05	0.000217	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TYMS—urinary bladder cancer	3e-05	0.00021	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.97e-05	0.000208	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.97e-05	0.000208	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.92e-05	0.000205	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.84e-05	0.000199	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.79e-05	0.000196	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.79e-05	0.000196	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.62e-05	0.000184	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.44e-05	0.000171	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.41e-05	0.000169	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.27e-05	0.000159	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.24e-05	0.000157	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.24e-05	0.000157	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.23e-05	0.000157	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.23e-05	0.000157	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.17e-05	0.000152	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.15e-05	0.00015	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.13e-05	0.000149	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ERCC2—urinary bladder cancer	2.11e-05	0.000148	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2.04e-05	0.000143	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.98e-05	0.000139	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.8e-05	0.000126	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.67e-05	0.000117	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.61e-05	0.000113	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.54e-05	0.000108	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.5e-05	0.000105	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.46e-05	0.000102	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.4e-05	9.79e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.39e-05	9.75e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.38e-05	9.67e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.38e-05	9.67e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.32e-05	9.26e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.3e-05	9.09e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.26e-05	8.85e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.22e-05	8.55e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.1e-05	7.72e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—EP300—urinary bladder cancer	1.05e-05	7.36e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.89e-06	6.93e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.5e-06	6.66e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.78e-06	5.45e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.78e-06	4.76e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.47e-06	4.54e-05	CbGpPWpGaD
